Rare and Orphan Diseases - Global Neurology Academy

17-32 of 71

Individualizing gMG Treatment: Defining Success With Each Patient
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiers
Individualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
- Omar Sinno, MD
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiers
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
- Michael Weiss, MD
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiers
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
- Sheetal Shroff, MD
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
CME/CE
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Stephen Chrzanowski, MD, PhD; Aravindhan Veerapandiyan, MD
1.00 credit
- Stephen Chrzanowski, MD, PhD
- Aravindhan Veerapandiyan, MD
1.00 credit
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiers
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Ryan Quigley
- Ryan Quigley
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiers
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiers
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiers
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
NeuroFrontiers
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
NeuroFrontiers
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
NeuroFrontiers
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
NeuroFrontiers
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
NeuroFrontiers
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
Treatment of a Broader Population of Patients With DMD
Treatment of a Broader Population of Patients With DMD
CME/CE
Treatment of a Broader Population of Patients With DMD
Crystal Proud, MD; Erika Finanger, MD, MS
1.00 credit
- Crystal Proud, MD
- Erika Finanger, MD, MS
1.00 credit
Identifying CIDP: A Guide to Risk Profiles and Clinical Presentation
Identifying CIDP: A Guide to Risk Profiles and Clinical Presentation
Global Neurology Academy
Identifying CIDP: A Guide to Risk Profiles and Clinical Presentation
Nicolas Dubuisson, MD; Ryan Quigley
- Nicolas Dubuisson, MD
- Ryan Quigley
Gene Therapy Safety in DMD: How to Identify Common Immune Reactions
Gene Therapy Safety in DMD: How to Identify Common Immune Reactions
NeuroFrontiers
Gene Therapy Safety in DMD: How to Identify Common Immune Reactions
Kaitlin Batley, MD
- Kaitlin Batley, MD

2/5